This novel randomized controlled trial (RCT) aims to fill this critical knowledge gap by systematically investigating the effects of a supervised resistance exercise intervention on sarcopenia progression and related clinical outcomes in women undergoing neoadjuvant chemotherapy for breast cancer. Targeting a cohort of 46 female patients aged 20 and older, the study is uniquely positioned to unravel the complexities of muscle preservation within the context of aggressive cancer treatment modalities. Executed under robust methodological standards, this trial promises to enhance therapeutic strategies significantly, ultimately improving patients’ quality of life and treatment tolerance.

The rationale underpinning the trial is deeply rooted in the multifactorial impact of sarcopenia on cancer management. Patients exhibiting significant muscle wasting are known to experience increased susceptibility to chemotherapy-induced toxicities, prolonged hospitalization, and reduced functional independence. Furthermore, existing literature highlights that sarcopenia can aggravate cancer-related symptoms such as fatigue, pain, and diminished physical performance, which cumulatively impair psychological and social well-being. As such, interventions targeting sarcopenia are not merely supportive but integral to comprehensive oncological care pathways.

By implementing a hybrid, expert-supervised resistance exercise regimen, the research team addresses a critical barrier to intervention feasibility—patient accessibility. Recognizing that physical debilitation, treatment side effects, and geographic constraints often limit consistent participation, the program offers both on-site and virtual training sessions. Each participant will engage in three 60-minute resistance exercise sessions per week, empowering patients with flexibility while ensuring adherence to rigorous exercise protocols. This innovative delivery model is anticipated to foster higher retention rates and robust data collection.

Alongside tracking changes in muscle mass, the trial will employ a battery of validated assessments, measuring muscle strength and physical performance as core indicators of sarcopenia reversal or stabilization. These objective physiological markers are complemented by self-reported evaluations of cancer-related symptoms and overall quality of life. The multidimensional outcome framework underscores the study’s commitment to capturing the comprehensive impact of resistance exercise, encompassing not only physical but also psychosocial dimensions of patient health.

Importantly, this investigation integrates a longitudinal design with multiple assessment timepoints—baseline, mid-intervention at six and twelve weeks, and upon program completion at eighteen weeks. Such granularity allows for dynamic tracking of intervention effects and the identification of critical windows during chemotherapy when resistance training may yield maximal benefit. The resulting data will inform optimal exercise prescription parameters tailored to the breast cancer neoadjuvant setting.

This RCT is situated within the institutional support of Yonsei University Health System’s Severance Hospital, adhering to stringent ethical standards under institutional review board approval. The prospective registration of the trial (Clinical Research Information Service, reference KCT0008961) further emphasizes transparency and scientific rigor, facilitating replication and inclusion in future meta-analyses.

Beyond direct clinical outcomes, the study has broader implications for oncology rehabilitation frameworks. The integration of prehabilitation exercise protocols into standard cancer care pathways demands evidence-based validation, particularly for vulnerable populations experiencing sarcopenia. Positive findings from this examination could serve as a catalyst for widespread implementation of resistance training as a non-pharmacological adjunct, potentially transforming supportive care paradigms and enhancing survivorship trajectories.

Current gaps in existing research often stem from heterogeneous study designs, small sample sizes, or retrospective analyses limiting causal inference. This trial’s randomized controlled design and hybrid delivery model mark a significant advance, providing high-quality evidence that is both internally valid and pragmatically feasible for real-world application. Addressing the challenge of neoadjuvant chemotherapy-associated sarcopenia with a multidisciplinary, exercise oncology approach resonates with contemporary calls for integrative cancer care.

Moreover, the focus on breast cancer, a disease with high global incidence and substantial survivorship populations, underscores the study’s public health relevance. Muscle preservation strategies that mitigate chemotherapy side effects could decrease healthcare utilization, reduce treatment interruptions, and improve long-term functional independence, all of which impart meaningful cost-effectiveness benefits.

Emerging mechanistic research also supports the biological plausibility of exercise-mediated sarcopenia mitigation. Resistance training is known to stimulate muscle protein synthesis via activation of mTOR pathways, enhance mitochondrial function, and reduce systemic inflammation—processes often dysregulated in cancer cachexia and treatment-induced muscle atrophy. This trial’s outcomes may provide clinical corroboration of these molecular insights in a cancer-specific cohort.

In conclusion, this pioneering RCT holds promise to reshape how oncologists and rehabilitation specialists approach musculoskeletal health in breast cancer patients receiving neoadjuvant chemotherapy. By rigorously examining resistance exercise as a prehabilitative strategy, the study aims to develop actionable, evidence-based interventions that integrate seamlessly into multidisciplinary cancer treatment plans. The anticipated results will not only clarify the role of exercise in sarcopenia management but also inspire future research into personalized, holistic cancer care.

As the oncology community continues to prioritize survivorship and quality of life, such innovative trials are indispensable in guiding clinical practice evolution. This research embodies the confluence of exercise science, oncology, and patient-centered care, marking an exciting frontier in supportive cancer therapies. The scientific and medical worlds eagerly await the insights this trial will yield, potentially heralding a new standard of care wherein resistance training becomes a routine, indispensable component of breast cancer treatment.

With enrollment commencing shortly and follow-up assessments meticulously planned, this study represents a beacon of hope for patients, clinicians, and researchers alike. Its outcomes could materially shift our understanding of how targeted physical interventions can modulate cancer treatment trajectories, enhancing resilience and wellbeing amidst the challenges of neoadjuvant chemotherapy. Ultimately, this endeavor epitomizes the spirit of translational medicine—turning laboratory and physiological knowledge into impactful clinical interventions that improve lives.

Subject of Research: Effects of resistance exercise intervention on sarcopenia in patients undergoing neoadjuvant chemotherapy for breast cancer.

Article Title: Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial

Article References:
Jang, M.K., Park, S., Jeon, J.Y. et al. Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial. BMC Cancer 25, 1296 (2025). https://doi.org/10.1186/s12885-025-14721-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14721-9

The study, detailed in the forthcoming issue of the Journal of Sport and Health Sciences, represents the first randomized controlled trial in humans to investigate the effects of prehabilitation—exercise performed during chemotherapy—on the tumor immune microenvironment specifically in oesophageal adenocarcinoma. This form of cancer, originating in the glandular cells of the oesophagus, remains a formidable clinical challenge, often presenting poor prognoses due to its aggressive nature and late diagnosis. The trial enrolled 22 patients from the Royal Surrey NHS Foundation Trust, a renowned cancer center, with eleven participants engaging in a 16-week structured exercise regimen, while eleven acted as controls without intervention.

The exercise protocol implemented consisted of two supervised sessions weekly during the chemotherapy phase, approximately spanning eight weeks, followed by a progressive exercise phase leading up to surgical resection. This regimen was meticulously designed to improve patients’ aerobic capacity and overall fitness, parameters believed to influence immune competence. Post-surgery, researchers harvested tumor specimens for in-depth immunological and genomic analyses. Utilizing multispectral immunohistochemistry, they quantified tumor-infiltrating immune cells, while gene expression profiling was conducted with NanoString technology, a high-throughput, precise method for measuring mRNA levels within tumor tissues.

Dr. Nicola Annels, co-senior author and cancer immunologist, highlighted the novelty of the findings, noting that this is the first trial to demonstrate a tangible modulation of the tumor microenvironment through exercise during chemotherapy. Specifically, tumors from patients undergoing the prehabilitation program exhibited a notable increase in cytotoxic immune populations, including CD8+ T cells and natural killer (NK) cells, which are critical effectors in antitumor immunity. These immune cells facilitate targeted destruction of cancer cells and have been correlated with improved responses to oncological treatments, implying that exercise may prime the tumor milieu for enhanced immunological assault.

Despite the promising results, Dr. Annels emphasized the exploratory nature of the study and the necessity for further research to consolidate these observations. Previous investigations, predominantly conducted in animal models, have suggested exercise-mediated enhancement of immune surveillance and suppression of tumor growth. However, analogous human studies, largely focused on prostate and colorectal cancers, failed to observe an increase in tumor-infiltrating immune cells, underscoring the complexity of translating preclinical findings into clinical practice.

The involvement of Dr. David Bartlett, co-first author and exercise physiologist, further elucidates the relationship between aerobic fitness and immune response. His team discovered a positive correlation between improvements in patients’ cardiorespiratory fitness and the density of immune cells within their tumors. Notably, they identified mature tertiary lymphoid structures—organized immune cell aggregates that function as local immune hubs—within tumor tissues from fitter individuals. The presence of these structures associates with heightened antitumor responses and better clinical outcomes, suggesting that exercise may facilitate the formation or maturation of these critical immune architectures.

The OPTIMUS trial, currently expanding with a target enrollment of 50 subjects, aims to robustly assess the impact of prehabilitation on clinical endpoints. Participants are randomized to either the previously tested moderate intensity exercise group or a novel higher intensity protocol hypothesized to elicit superior immunomodulatory effects. Preliminary data from seven patients already enrolled in OPTIMUS have revealed cases of complete tumor regression where no residual tumor was detected during operative examination—a rare phenomenon occurring in only about 6% of such patients under standard care. This early indication, while anecdotal, alludes to the transformative potential of exercise interventions in neoadjuvant cancer therapy.

Clinically, patients involved in the trial have exhibited improved physical resilience, translating into better perioperative outcomes and enhanced recovery trajectories. Mr. Charles Rayner, co-first author and specialist surgeon, remarked on the increased fitness levels allowing patients to withstand surgical stress and recuperation more effectively. This functional improvement is pivotal given that surgical morbidity and mortality remain significant concerns in oesophageal cancer management.

Senior author Mr. Nima Abbassi-Ghadi underscored the real-world impact of these findings, affirming that patient feedback overwhelmingly reflects augmented well-being and capability through preoperative exercise engagement. Remarkably, some participants who might otherwise have been ineligible for curative surgery due to frailty have attained sufficient fitness levels to undergo successful resections, highlighting the pragmatic implications of integrating structured exercise into therapeutic pathways.

Patient testimonies provide a poignant narrative complementing the scientific data. One participant described the OPTIMUS program as a vital source of agency and support amid the turmoil of cancer treatment. The emotional intelligence and personalized care offered by the research team were as critical as the physical conditioning itself, illustrating the holistic benefits—both psychological and physiological—that exercise prehabilitation confers during oncological care.

Researchers encourage eligible patients receiving treatment at Royal Surrey Cancer Centre to inquire about participation in the ongoing trial. Direct contact can be made via Dr. Bartlett and Dr. Annels, endorsing a collaborative and accessible research environment focused on transforming cancer treatment paradigms.

This study was generously funded by the World Cancer Research Fund as part of their International grant program, reflecting a global commitment to innovative cancer research that bridges basic science and clinical application. The emerging evidence from this research promises to redefine the role of exercise as a potent adjunct in cancer therapy, fostering a multidisciplinary approach to improving patient survival and quality of life.

Subject of Research: Effects of structured exercise prehabilitation during neoadjuvant chemotherapy on tumor-infiltrating immune cells in oesophageal adenocarcinoma

Article Title: Prehabilitation during neoadjuvant chemotherapy results in an enhanced immune response in oesophageal adenocarcinoma tumours: a randomised controlled trial

News Publication Date: 9-Jun-2025

Web References:
DOI link

References:
Available upon embargo lift through mediarelations@surrey.ac.uk

Image Credits:
An image of Dr. Nicola Annels and Dr. David Bartlett available via contact with mediarelations@surrey.ac.uk

Keywords: Cancer immunology, Esophageal cancer, Cancer cells, Cancer research, Oncology, Physical exercise